Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study.

Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).Results: In this study, treatment with a combination of anti-PD-1 antibody and GnP regimen for pancreatic cancer resulted in partial response (PR) for 10 out of 27 (37.04%) patients, stable disease (SD) for 10 (37.04%) patients, and progressive disease (PD) for 7 (25.92%) patients. The study found that the median OS (mOS) for these patients was 16.4 months [standard error (SE) = 1.117, 95% confidence interval (CI) 14.211– 18.589], while the median PFS (mPFS) was 6.4 months (SE = 1.217, 95% CI 3.981– 8.752). Subgroup analysis revealed that pancreatic cancer patients' Eastern Cooperative Oncology Group (ECOG) performance status (PS) (0 vs 1) and treatment cycles (≤ 6 cycles vs > 6 cycles) significantly affected OS and PFS. Patients experienced mostly grade 1– 2 adverse events (AEs), which were relieved through clinical treatment.Conclusion: The combination of GnP with anti-PD-1 antibodies shows promise as a potential treatment option for advanced pancreatic cancer. [ABSTRACT FROM AUTHOR]